Research Article
Downregulated mRNA Expression of ZNF385B Is an Independent Predictor of Breast Cancer
Table 2
Correlation between clinicopathological characteristics and ZNF385B expression in breast cancer patients’ samples.
| | Parameters | Variable | N | ZNF385B expression | χ2 | p value | | High (N%) | Low (N%) |
| | Age | <60 | 589 | 436 (54.3) | 153 (51.17) | 0.856 | 0.355 | | ≥60 | 513 | 367 (45.7) | 146 (48.83) |
| | Gender | Female | 1090 | 795 (99) | 295 (98.66) | 0.025 | 0.873 | | Male | 12 | 8 (1) | 4 (1.34) |
| | Histological type | Infiltrating ductal carcinoma | 790 | 551 (68.7) | 239 (79.93) | 22.841 | <0.001 | | Infiltrating lobular carcinoma | 204 | 176 (21.95) | 28 (9.36) | | Other | 107 | 75 (9.35) | 32 (10.7) |
| | Molecular subtype | Basal | 142 | 76 (12.1) | 66 (29.86) | 61.651 | <0.001 | | HER-2 | 67 | 44 (7.01) | 23 (10.41) | | LumA | 422 | 355 (56.53) | 67 (30.32) | | LumB | 194 | 132 (21.02) | 62 (28.05) | | Normal | 24 | 21 (3.34) | 3 (1.36) |
| | ER | Indeterminate | 2 | 1 (0.13) | 1 (0.35) | 43.781 | <0.001b | | Negative | 239 | 134 (17.4) | 105 (36.97) | | Positive | 813 | 635 (82.47) | 178 (62.68) |
| | PR | Indeterminate | 4 | 3 (0.39) | 1 (0.35) | 71.900 | <0.001b | | Negative | 345 | 194 (25.19) | 151 (53.36) | | Positive | 704 | 573 (74.42) | 131 (46.29) |
| | HER-2 | Equivocal | 180 | 127 (18.84) | 53 (21.46) | 3.960 | 0.266 | | Indeterminate | 12 | 7 (1.04) | 5 (2.02) | | Negative | 565 | 425 (63.06) | 140 (56.68) | | Positive | 164 | 115 (17.06) | 49 (19.84) |
| | Menopause status | Inde | 34 | 21 (2.86) | 13 (4.71) | 3.811 | 0.283 | | Peri | 40 | 32 (4.35) | 8 (2.9) | | Post | 706 | 509 (69.25) | 197 (71.38) | | Pre | 231 | 173 (23.54) | 58 (21.01) |
| | T classification | T1 | 281 | 220 (27.4) | 61 (20.4) | 8.685 | 0.069 | | T2 | 640 | 455 (56.66) | 185 (61.87) | | T3 | 138 | 102 (12.7) | 36 (12.04) | | T4 | 40 | 24 (2.99) | 16 (5.35) | | TX | 3 | 2 (0.25) | 1 (0.33) |
| | N classification | N0 | 516 | 374 (46.58) | 142 (47.49) | 6.606 | 0.158 | | N1 | 367 | 276 (34.37) | 91 (30.43) | | N2 | 120 | 85 (10.59) | 35 (11.71) | | N3 | 79 | 58 (7.22) | 21 (7.02) | | NX | 20 | 10 (1.25) | 10 (3.34) |
| | M classification | M0 | 917 | 669 (83.31) | 248 (82.94) | 4.062 | 0.131 | | M1 | 22 | 12 (1.49) | 10 (3.34) | | MX | 163 | 122 (15.19) | 41 (13.71) |
| | TNM stage | I | 182 | 145 (18.19) | 37 (12.46) | 10.100 | 0.039 | | II | 626 | 448 (56.21) | 178 (59.93) | | III | 252 | 184 (23.09) | 68 (22.9) | | IV | 20 | 10 (1.25) | 10 (3.37) | | X | 14 | 10 (1.25) | 4 (1.35) |
| | Margin status | Close | 31 | 24 (3.2) | 7 (2.47) | 0.596 | 0.742 | | Negative | 922 | 666 (88.92) | 256 (90.46) | | Positive | 79 | 59 (7.88) | 20 (7.07) |
| | Vital status | Deceased | 155 | 91 (11.33) | 64 (21.4) | 18.287 | <0.001 | | Living | 947 | 712 (88.67) | 235 (78.6) |
| | Radiation therapy | No | 445 | 319 (43.58) | 126 (46.67) | 0.762 | 0.383 | | Yes | 557 | 413 (56.42) | 144 (53.33) |
| | Neoadjuvant treatment | No | 1088 | 795 (99) | 293 (98.32) | 0.380 | 0.538 | | Yes | 13 | 8 (1) | 5 (1.68) |
| | Targeted molecular therapy | No | 46 | 34 (7.96) | 12 (7.89) | 0.001 | 0.979 | | Yes | 533 | 393 (92.04) | 140 (92.11) |
| | Sample type | Metastatic | 7 | 6 (0.75) | 1 (0.33) | 0.118 | 0.732 | | Primary tumor | 1097 | 798 (99.25) | 299 (99.67) |
| | OS | 0 | 933 | 702 (88.52) | 231 (78.57) | 17.473 | <0.001 | | 1 | 154 | 91 (11.48) | 63 (21.43) |
| | RFS | 0 | 816 | 617 (91.54) | 199 (83.61) | 11.743 | <0.001 | | 1 | 96 | 57 (8.46) | 39 (16.39) |
|
|
ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor-2; T: tumor; M: metastasis; N: node; OS: overall survival; RFS: relapse-free survival. bFisher’s exact test.
|
